3-isomangostin

3-Isomangostin

1. Identity and Chemical Characterization

Chemical Names and Identifiers

3-Isomangostin is a naturally occurring prenylated xanthone derivative classified within the broader family of mangosteen xanthones. According to ChEBI, 3-isomangostin is a member of the xanthones. Its systematic IUPAC name is 3,4-dihydro-5,9-dihydroxy-8-methoxy-2,2-dimethyl-7-(3-methyl-2-butenyl)-2H,6H-pyrano[3,2-b]xanthen-6-one. The compound is also designated in chemical databases under the synonyms 5,9-dihydroxy-8-methoxy-2,2-dimethyl-7-(3-methyl-2-buten-1-yl)-3,4-dihydro-2H,6H-pyrano[3,2-b]xanthen-6-one and ISOMANGOSTIN, 3-. Its molecular formula is C₂₄H₂₆O₆ and it is registered in PubChem under CID 13873655. The CAS Registry Number is 19275-46-8. A monohydrate form (C₂₄H₂₈O₇) also exists and is catalogued under PubChem CID 13873658.

Structural Relationship to α-Mangostin

α-Mangostin is a natural xanthone from mangosteen pericarp; 3-isomangostin is a cyclized derivative of α-mangostin. The cyclization introduces a dihydropyran ring at the 3,4-position of the xanthone scaffold, distinguishing it structurally from the open-chain prenyl group found in α-mangostin. Xanthone itself is a heterocyclic compound with a dibenzo-γ-pyrone framework, well-known for privileged structures in biological activity. The wide biological activity of xanthones is produced by caspase activation, RNA binding, DNA cross-linking, as well as P-gp, kinase, aromatase, and topoisomerase inhibition; this activity depends on the type, number, and position of the attached functional groups in the xanthone skeleton.

Botanical Source

Garcinia mangostana L. (Clusiaceae) is well known in southeastern Asia for its pleasant-tasting fruits, commonly known as mangosteen, which is now used widely as a botanical dietary supplement. It is cultivated in the tropical rainforests of several Southeast Asian nations, including Indonesia, Malaysia, Sri Lanka, the Philippines, and Thailand. The origin of the mangosteen tree is not clearly understood; however, it may have possibly originated in Malaysia and can now be found in hot and humid regions throughout Southeast Asia, Central America, and Africa.

At least 68 distinct xanthones have been identified in different parts of the G. mangostana plant, with 50 being present in the fruit's pericarp at higher concentrations than in the aril or edible portion of the fruit. The xanthones of mangosteen include α-mangostin, β-mangostin, γ-mangostin, gartanine, 8-deoxygartanine, mangostinone, 11α-mangostin, mangostanol, 1-isomangostin, 3-isomangostin, and garcinone E, with the most abundant xanthones in the pericarp and bark being α- and γ-mangostin.

Plant Parts Yielding 3-Isomangostin

3-Isomangostin has been isolated from multiple anatomical parts of Garcinia mangostana. Chemical investigation of dichloromethane extracts of the freeze-dried G. mangostana pulp led to the isolation of δ-tocotrienol, α-mangostin, 3-isomangostin, stigmasterol, triacylglycerols, and other compounds from the pulp. Additionally, bioassay-guided fractionation of a chloroform-soluble extract of Garcinia mangostana stem bark led to the isolation of 3-isomangostin along with several other known xanthones; compounds 2–4, 9, and 10 were isolated as constituents of the stem bark part of this plant for the first time. The isolation from the pericarp of G. mangostana, structure elucidation, and antimicrobial assay of 3-isomangostin has also been reported from Philippine collections of G. mangostana.

2. Traditional and Historical Use

Ethnobotanical Context

Early reports of the traditional uses of infusions and decoctions of mangosteen peels and seeds to treat gastrointestinal and urinary tract infections, and as anti-scorbutic, laxative, and anti-fever agents, date from almost two hundred years ago, with documented references from Descourtilz et al. (1821), Lilly and Colman (1833), and Pardo de Tavera and Thomas (1901).

People in Southeast Asian countries have used the pericarp (peel, rind, hull, or ripe) of Garcinia mangostana as a traditional medicine for the treatment of abdominal pain, diarrhea, dysentery, infected wounds, suppuration, and chronic ulcer. Different formulations of the mangosteen, including teas, ointments, tinctures, and other preparations, have been used in traditional Eastern medicine to treat skin infections, urinary tract infections, dysentery, inflammation, abdominal pain, diarrhea, and fevers.

Specific Traditional Systems

In Ayurvedic medicine, the pericarp is used to alleviate digestive issues and promote healthy skin, while in Chinese traditional medicine it is believed to have cooling properties and is used to reduce fever, alleviate pain, and treat diarrhea. Species of Garcinia have been used to combat malaria in traditional African and Asian medicines.

It is important to note that these historical and traditional applications are attributed to preparations of the whole pericarp extract or whole-plant preparations of G. mangostana — preparations that contain a complex mixture of xanthones including α-mangostin, γ-mangostin, gartanin, and 3-isomangostin, among many others. 3-Isomangostin as an isolated, specific compound was not the object of traditional medicinal practice; it was identified and characterized only with modern phytochemical analytical methods.

3. Phytochemical Context: Xanthones of Garcinia mangostana

The Xanthone Scaffold

The primary phytochemicals present in the mangosteen species are isoprenylated xanthones, a class of secondary metabolites with multiple reports of biological effects including antioxidant, proapoptotic, antiproliferative, antinociceptive, anti-inflammatory, neuroprotective, hypoglycemic, and antiobesity activities. Isoprene, methoxyl, and hydroxyl groups located at various positions on the A and B rings of the xanthone scaffold result in a diverse array of xanthone compounds.

Chemically diverse xanthone analogs are the most characteristic secondary metabolites from this plant, and their activity has been evaluated against a wide variety of biological targets.

Position of 3-Isomangostin Among Mangosteen Xanthones

3-Isomangostin is considered a minor xanthone compared to α- and γ-mangostin, which are the most abundant and most studied. The most abundant xanthones in the pericarp of mangosteen fruit are α- and γ-mangostin; other xanthones in mangosteen pericarp include β-mangostin, gartanin, 8-deoxygartanin, garcinones A, B, C, D and E, mangostinone, 9-hydroxycalabaxanthone, and isomangostin, among others. Despite being present in lower concentrations, 3-isomangostin has attracted substantial biochemical research interest due to several potent and distinctive interactions with high-priority biological targets.

4. Key Biological Activities and Mechanisms of Action

4.1 MTH1 (MutT Homolog 1) Inhibition — Anticancer Target

The most pharmacologically notable activity ascribed specifically to 3-isomangostin is its exceptionally potent inhibition of the enzyme MutT Homolog 1 (MTH1, also known as NUDT1). Cancer cells are dependent on MTH1 activity for survival due to the high level of reactive oxygen species in cancer cells; therefore, MTH1 is considered to be a novel target for treatment of various cancers.

Aiming to discover novel MTH1 inhibitors, Yokoyama et al. performed X-ray crystallographic screening by soaking MTH1–(R)-crizotinib complex crystals into cocktails containing 62 natural products or 33 synthetic compounds, and first identified phenol-bearing α-mangostin as a hit, with an IC₅₀ of 0.47 μmol/L. An inhibition assay against nine additional natural xanthone derivatives then revealed 3-isomangostin as the most potent inhibitor, with an IC₅₀ value of 52 nmol/L; it was speculated that mangostins might exhibit their antitumor activities against a broad spectrum of cancer cells by inhibiting MTH1 activities.

Detailed structural analyses of the MTH1–3-isomangostin complex showed the novel binding mode of 3-isomangostin; the authors suggest that 3-isomangostin would be an attractive chemical tool for the development of anticancer agents. This study, published in 2019, represents the highest pharmacological potency yet reported for 3-isomangostin at any defined molecular target.

4.2 Cytotoxicity Against Cancer Cell Lines

3-Isomangostin was isolated from Garcinia mangostana stem bark and exhibited cytotoxicity against the HT-29 human colon cancer cell line with an ED₅₀ value of 4.9 μM. This was determined via bioassay-guided fractionation using a chloroform-soluble extract, in a study that simultaneously evaluated the NF-κB pathway. Notably, while α-mangostin (ED₅₀ 1.7 μM) and β-mangostin (ED₅₀ 1.7 μM) displayed greater potency against this cell line, 3-isomangostin's cytotoxicity was still in a low-micromolar range.

Xanthone as a class is a heterocyclic compound with a dibenzo-γ-pyrone framework well-known to possess "privileged structures" for anticancer activities against several cancer cell lines. Prenyl substituents are reported as a pivotal functional group for the anticancer activity of xanthones; the introduction of a prenyl group to the 1-hydroxyxanthone scaffold has been shown to dramatically increase anticancer activity against MCF-7 cells. The cyclized prenyl (dihydropyran) moiety in 3-isomangostin represents a variant of this prenyl substitution pattern.

4.3 Human Aldose Reductase Inhibition

Investigators studying aldose reductase inhibition from Garcinia mangostana from Indonesia found that the dichloromethane extract of the root bark demonstrated an IC₅₀ value of 11.98 μg/mL for human aldose reductase in vitro, and from this fraction, 3-isomangostin was discovered to be the most potent isolate against aldose reductase, with an IC₅₀ of 3.48 μM. Aldose reductase is the rate-limiting enzyme in the polyol metabolic pathway; an inhibitor for aldose reductase is expected to serve as a medicine for diabetic complications — diseases arising from diabetes such as diabetic neuropathy, diabetic cataract, diabetic keratopathy, diabetic retinopathy, and diabetic nephropathy. This property positions 3-isomangostin as a potential lead for investigating protection against diabetes-associated organ damage.

4.4 Acetylcholinesterase (AChE) Inhibition

A study investigating acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activities of G. mangostana extract and its chemical constituents using Ellman's colorimetric method found six bioactive prenylated xanthones showing moderate to potent cholinesterase inhibition with IC₅₀ values lower than 20.5 μM. Among the xanthones, mangostanol, 3-isomangostin, garcinone C, and α-mangostin are AChE-selective inhibitors, while 8-deoxygartanin is a BChE selective inhibitor and γ-mangostin is a dual inhibitor. The selective inhibition of AChE has relevance for potential cognitive and neurodegenerative disease applications, as AChE inhibitors are a major pharmacological class used in Alzheimer's disease management.

4.5 Antiplasmodial Activity

The xanthones α-mangostin, β-mangostin, and 3-isomangostin, known from G. mangostana, showed antiplasmodial activity with IC₅₀ values in the range of 4.71–11.40 μM in the plasmodial lactate dehydrogenase assay. Artemisinin and chloroquine were used as positive controls and exhibited IC₅₀ values in the range of 0.01–0.24 μM. While the antiplasmodial activity is present, it is considerably weaker than established antimalarial drugs, and the significance lies primarily as a lead for structure-activity relationship studies. The identification of antiplasmodial xanthone compounds from G. mangostana provides evidence for the antiplasmodial activity of Garcinia species and warrants further investigation of these fruits as dietary sources of chemopreventive compounds.

4.6 Transthyretin (TTR) Amyloidogenesis Inhibition

Transthyretin (TTR) is a homotetrameric protein involved in human hereditary amyloidoses; the discovery and development of small molecules that inhibit amyloid fibril formation of TTR is one of the therapeutic strategies for these diseases. Five different V30M TTR mutant crystal structures were solved in complex with γ-M, α-M, and 3-isomangostin. The most promising TTR stabilizers among the tested xanthones were γ-M and α-mangostin, while 3-isomangostin, the cyclized derivative of α-M, displayed significantly lower capability to inhibit the fibrillization process. Thus, while 3-isomangostin has been characterized structurally in the TTR binding pocket, its activity in this context is notably weaker than its parent compound α-mangostin.

4.7 Free Radical Scavenging (Antioxidant Activity)

3-Isomangostin has free radical scavenging activity. Excess of reactive oxygen species and reactive nitrogen species has been found to be linked to various diseases including cancer, cardiovascular disorders, diabetes mellitus, inflammation, and neurodegenerative diseases. The antioxidant activity of 3-isomangostin has been reported in the literature, attributable to the phenolic hydroxyl groups of the xanthone scaffold, which are capable of donating hydrogen atoms to neutralize reactive species. This is a class-wide property shared with other mangosteen xanthones.

4.8 Anti-Inflammatory Activity

Mangostin, a naturally occurring xanthone in the rinds of fruits of Garcinia mangostana Linn. (Guttiferae), and its derivatives including 1-isomangostin, mangostin triacetate, and others were screened for various pharmacological effects in experimental animals. Mangostin, 1-isomangostin, and mangostin triacetate produced pronounced anti-inflammatory activity both by intraperitoneal and oral routes in rats as tested by carrageenan-induced hind paw edema, cotton pellet implantation, and granuloma pouch techniques. Although this early study (PubMed PMID 314790) examined 1-isomangostin rather than 3-isomangostin directly, it provides important pharmacological context for the isomangostin subclass. Anti-inflammatory activity was observed even in bilaterally adrenalectomized rats, suggesting a mechanism independent of adrenal corticosteroid pathways.

In pharmaceuticals and medicinal chemistry, 3-isomangostin is studied as a bioactive lead and scaffold for xanthone-based drug discovery, with reported antimicrobial and anti-inflammatory activities in preclinical studies.

4.9 Antimicrobial Activity

The isolation from the pericarp of G. mangostana, structure elucidation, and antimicrobial assay of 3-isomangostin has been reported by investigators in the Philippines. Antimicrobial testing of xanthone-containing extracts and isolated xanthones from mangosteen has been a recurring theme in the literature since the 1980s. 3-Isomangostin has been evaluated alongside other xanthones in these assays, though the most potent antibacterial activity within the xanthone class is typically attributed to α-mangostin.

5. Scientific Evidence by Area — Summary and Strength of Evidence

5.1 Oncology / Cancer Research

Evidence base: In vitro (cell-based) and biochemical (enzyme inhibition); no human or animal studies have been conducted specifically with isolated 3-isomangostin.

The principal anticancer evidence for 3-isomangostin rests on two mechanistic streams. First, its cytotoxicity against HT-29 human colon cancer cells (ED₅₀ 4.9 μM) demonstrated in a Journal of Natural Products study (2010, PMID 19839614) using bioassay-guided fractionation. Second, and more pharmacologically compelling, is its potent MTH1 enzyme inhibition. In the Yokoyama et al. study, X-ray crystallographic screening using cocktails of natural products identified α-mangostin as an initial MTH1 hit with an IC₅₀ of 0.47 μmol/L. Subsequent inhibition assays against additional natural xanthone derivatives revealed 3-isomangostin as the most potent MTH1 inhibitor with an IC₅₀ value of 52 nmol/L.

Evidence strength: Preliminary — entirely in vitro and biochemical. No animal model data and no clinical data exist specifically for 3-isomangostin as an anticancer agent. Despite consistently impressive preclinical findings across anticancer research for mangosteen xanthones broadly, almost no well-designed clinical trials have confirmed therapeutic benefits for any condition in humans.

5.2 Diabetic Complications (Aldose Reductase Pathway)

Evidence base: In vitro enzyme inhibition assay only.

The demonstration that 3-isomangostin is the most potent human aldose reductase inhibitor isolated from G. mangostana root bark dichloromethane extract (IC₅₀ 3.48 μM) comes from a single published in vitro study. Aldose reductase is implicated as a rate-limiting enzyme whose inhibition may protect against diabetic complications including diabetic neuropathy, diabetic cataract, diabetic keratopathy, diabetic retinopathy, and diabetic nephropathy. No in vivo or human data exist for 3-isomangostin in this context.

Evidence strength: Very preliminary — a single in vitro biochemical finding; no animal or clinical validation has been published for 3-isomangostin specifically.

5.3 Neuroscience — Cholinesterase Inhibition (Potential Alzheimer's Relevance)

Evidence base: In vitro enzyme inhibition, with molecular docking analysis.

In a study investigating AChE and BChE inhibitory activities of G. mangostana extract and constituents using Ellman's colorimetric method, cholinesterase inhibitory-guided approaches led to identification of six bioactive prenylated xanthones showing moderate to potent inhibition with IC₅₀ values below 20.5 μM. 3-Isomangostin was among the AChE-selective inhibitors identified. Molecular docking studies accompanied the experimental findings. No in vivo or clinical data exist for 3-isomangostin in neurological indications.

Evidence strength: Very preliminary — in vitro and computational only.

5.4 Antiparasitic (Malaria)

Evidence base: In vitro plasmodial lactate dehydrogenase assay.

3-Isomangostin showed antiplasmodial activity with IC₅₀ values in the range of 4.71–11.40 μM against Plasmodium falciparum. These values are substantially weaker than the reference drugs artemisinin and chloroquine (IC₅₀ 0.01–0.24 μM), and no in vivo antimalarial studies with isolated 3-isomangostin have been reported.

Evidence strength: Very preliminary — in vitro; the compound's relative potency is considerably lower than established antimalarials.

5.5 Amyloid Disease (TTR Amyloidosis)

Evidence base: In vitro binding assays and X-ray crystallographic structural data.

Five different V30M TTR mutant crystal structures were solved in complex with γ-M, α-M, and 3-isomangostin, establishing structural data for all three compounds at the TTR binding site. However, among the tested xanthones, 3-isomangostin displayed significantly lower capability to inhibit the TTR fibrillization process compared with γ-M and α-mangostin. This places 3-isomangostin as a structurally informative but pharmacologically weaker candidate in this particular area compared to related xanthones.

Evidence strength: Very preliminary — structural and in vitro data only; 3-isomangostin is not the lead compound in this area.

5.6 Antioxidant Activity

Evidence base: In vitro free radical scavenging assays; no human studies.

Free radical scavenging activity has been reported for 3-isomangostin and is consistent with the known antioxidant properties of the mangosteen xanthone class broadly. Various health-promoting activities of xanthones in the pericarp of mangosteen fruit have been described by numerous investigators using in vitro cellular models; during the past several years, anti-tumorigenic and anti-inflammatory activities of xanthones have been demonstrated in laboratory rodents; controlled intervention trials of the efficacy of xanthones in human volunteers remain quite limited.

Evidence strength: In vitro only for 3-isomangostin specifically; the broader mangosteen xanthone class has limited human bioavailability data.

6. Body Systems and Health Areas Associated with 3-Isomangostin

• Oncology/Cancer Biology: MTH1-targeted DNA damage response; colon cancer cytotoxicity (HT-29 cells).
• Metabolic/Endocrine: Aldose reductase inhibition relevant to the polyol pathway and diabetic complications.
• Neurological: Acetylcholinesterase inhibition (cholinergic system); structural interaction with TTR, a protein involved in hereditary amyloidoses.
• Infectious Disease: Antiplasmodial activity (Plasmodium falciparum); antimicrobial properties in preclinical models.
• Immune/Inflammatory: Anti-inflammatory properties reported for the isomangostin class in animal models; free radical scavenging.
• Cardiovascular: Class-wide cardioprotective studies on mangosteen xanthones exist, but specific data for 3-isomangostin are sparse.

7. Dosage Forms and Reported Concentrations in Studies

No clinical trials or regulatory submissions have been conducted for 3-isomangostin as an isolated, single-compound supplement. The compound is therefore not associated with any established therapeutic or supplemental dose. Concentrations used in published preclinical research are as follows (as stated directly in study reports):

• MTH1 inhibition (biochemical assay): 3-Isomangostin was the most potent MTH1 inhibitor with an IC₅₀ value of 0.052 μM (52 nM).
• HT-29 colon cancer cytotoxicity (in vitro): 3-Isomangostin exhibited cytotoxicity against the HT-29 cell line with an ED₅₀ value of 4.9 μM.
• Aldose reductase inhibition (in vitro, enzyme assay): 3-Isomangostin was the most potent isolate against human aldose reductase with an IC₅₀ of 3.48 μM.
• Antiplasmodial activity (in vitro): 3-Isomangostin showed antiplasmodial activity with IC₅₀ values in the range of 4.71–11.40 μM.
• Acetylcholinesterase inhibition (in vitro): Six bioactive prenylated xanthones including 3-isomangostin showed moderate to potent cholinesterase inhibition with IC₅₀ values below 20.5 μM.

Regarding broader mangosteen xanthone bioavailability — which provides relevant context — pericarp particles account for 1% of the mass but 99% of total xanthone content in mangosteen juice; in one human study, a 2-ounce serving of 100% mangosteen juice provided 130 ± 2 mg total xanthones. A study investigating the absorption of xanthone-rich mangosteen liquid in healthy human volunteers after acute consumption of 59 mL of a supplement containing mangosteen, aloe vera, green tea, and multivitamins found that α-mangostin was bioavailable and antioxidant capacity (ORAC assay) was increased by up to 18% after 2 h, with the increased antioxidant level lasting at least 4 h. However, this study assessed the mixture of xanthones, not isolated 3-isomangostin specifically.

8. Safety Considerations and Drug Interactions

Absence of Specific Human Safety Data for 3-Isomangostin

No human clinical trials, pharmacokinetic studies, or formal toxicology reports have been published for 3-isomangostin as an isolated compound. The compound is available commercially only as a research reagent (typically as a powder, or dissolved in DMSO at 10 mM concentration for laboratory use). It is not available as a marketed dietary supplement in isolated form.

Bioavailability Considerations Relevant to the Xanthone Class

The first report on xanthone bioaccessibility used a coupled in vitro digestion/Caco-2 human intestinal cell model; optimal bioaccessibility of mangosteen xanthones was dependent on incorporation into bile salt mixed micelles, and α-mangostin was transported across the apical surface of enterocyte-like Caco-2 cells and partially converted to phase II metabolites; transepithelial transport was enhanced by addition of products of lipid digestion, suggesting absorption was dependent on the assembly and secretion of chylomicrons. The fat-solubility of xanthones suggests their absorption may be meaningfully affected by co-ingestion with dietary fat.

General Evidence Gaps and Safety Uncertainty

Controlled intervention trials of the efficacy of xanthones in human volunteers, as well as characterization of absorption, metabolism, and elimination of these compounds, remain quite limited; the potential toxicity of chronic ingestion of formulations containing mangosteen pericarp and its extracts has received minimal attention.

Despite the numerous health claims on advertising sites for producers and retailers of products and beverages containing mangosteen, there is insufficient scientific evidence at this time to support the use of mangosteen-containing supplements as enhancers of health and useful adjuvants for treatment of various pathophysiological illnesses. This conclusion from a peer-reviewed critical review (Nutrients, 2013) applies with even greater force to 3-isomangostin as an isolated compound, for which neither efficacy nor long-term safety has been characterized in humans.

CNS Effects Reported in Animal Studies for Xanthone Derivatives

With the exception of one dimethylated derivative, all test compounds in a pharmacological profiling study (including mangostin derivatives) produced CNS depression characterized by ptosis, sedation, decreased motor activity, potentiation of pentobarbital sleeping time, and ether anesthesia in mice and rats. Although this refers primarily to 1-isomangostin and other derivatives rather than 3-isomangostin directly, it raises a class-level concern for CNS effects that would need to be specifically evaluated for 3-isomangostin.

Regulatory Status

3-Isomangostin has not been assigned a formal regulatory classification by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or the European Food Safety Authority (EFSA) as a supplement or drug ingredient in its isolated form. Mangosteen fruit and whole pericarp extracts have been used in food and beverage products in some jurisdictions. No monograph exists for 3-isomangostin in the WHO, ESCOP, German Commission E, or European Pharmacopoeia references.

9. Summary of Evidence Quality

The totality of evidence on 3-isomangostin is characterized by the following:

• All findings to date are from in vitro biochemical assays, cell culture models, or X-ray crystallography; no animal efficacy studies specifically using isolated 3-isomangostin have been published, and no human clinical data exist.
• The most compelling pharmacological finding is the sub-100 nM MTH1 inhibition (IC₅₀ 52 nM), which is of significant interest for cancer drug discovery but remains at the hit/lead identification stage.
• The compound's potent aldose reductase inhibition (IC₅₀ 3.48 μM) and selective AChE inhibition provide plausible mechanistic rationale for further investigation in metabolic and neurological disease models.
• Controlled intervention trials of the efficacy of xanthones in human volunteers, as well as characterization of absorption, metabolism, and elimination of these compounds, remain quite limited.
• 3-Isomangostin functions primarily as a research tool and drug-discovery lead within the xanthone chemical space, rather than as an established dietary supplement with demonstrated clinical efficacy.

References

• PubChem CID 13873655 — 3-Isomangostin (NIH/NLM)
• Iinuma M et al. Cytotoxic xanthone constituents of the stem bark of Garcinia mangostana (mangosteen). Journal of Natural Products, 2010. PubMed PMID 19839614
• Iinuma M et al. Cytotoxic Xanthone Constituents of the Stem Bark of Garcinia mangostana. PMC Full Text
• Yokoyama T et al. Discovery of a new class of MTH1 inhibitor by X-ray crystallographic screening. PubMed 2019. PMID 30771603
• Cianci M et al. Natural compounds as inhibitors of transthyretin amyloidosis and neuroprotective agents: analysis of structural data for future drug design. PMC 2020
• PMC: Targeting human MutT homolog 1 (MTH1) for cancer eradication: current progress and perspectives
• Ang KP et al. Prenylated xanthones from mangosteen as promising cholinesterase inhibitors and their molecular docking studies. PubMed 2014. PMID 25172794
• Lyles JT et al. In vitro antiplasmodial activity of benzophenones and xanthones from edible fruits of Garcinia species. Planta Medica 2014. PMID 24963617
• Shankaranarayan D et al. Pharmacological profile of mangostin and its derivatives. Archives Internationales de Pharmacodynamie et de Thérapie, 1979. PMID 314790
• Gutierrez-Orozco F, Failla ML. Biological Activities and Bioavailability of Mangosteen Xanthones: A Critical Review of the Current Evidence. Nutrients 2013. PMC3775248
• Balunas MJ et al. Structural Characterization, Biological Effects, and Synthetic Studies on Xanthones from Mangosteen (Garcinia mangostana). PMC3090081
• Yokoyama T et al. Discovery of γ-Mangostin as an Amyloidogenesis Inhibitor. Scientific Reports 2015
• An Update on the Anticancer Activity of Xanthone Derivatives: A Review. Pharmaceuticals 2021. PMC8625896
• Pedraza-Chaverri J et al. Medicinal properties of mangosteen (Garcinia mangostana L.): A comprehensive update. Food and Chemical Toxicology 2017
• The purple mangosteen (Garcinia mangostana): Defining the anticancer potential of selected xanthones. PMC 2022
• Chitchumroonchokchai C et al. Bioavailability and Antioxidant Effects of a Xanthone-Rich Mangosteen Product in Humans. Journal of Agricultural and Food Chemistry 2009
• Chemical Compounds and Pharmacological Activities of Mangosteen. Biointerface Research in Applied Chemistry 2022
• RCSB PDB 6AA5: Crystal structure of MTH1 in complex with 3-isomangostin
• RCSB PDB 4Y9G: Crystal structure of V30M mutated transthyretin in complex with 3-isomangostin